Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Genedrive plc (LSE:GDR): The Next Catalyst Investors Should Watch on the AIM Market

Genedrive plc (LSE:GDR) is a company to assess through the lens of rapid molecular diagnostic testing and pharmacogenetic testing technology. For investors following the London Stock Exchange’s AIM market, the central question is not simply whether the share price is moving on a particular …

Ankur Sharma | 14 October 2026

ImmuPharma plc (LSE:IMM): The Next Catalyst Investors Should Watch on the AIM Market

ImmuPharma plc (LSE:IMM) is a company to assess through the lens of drug discovery and development, including immunology and autoimmune-disease programmes. For investors following the London Stock Exchange’s AIM market, the central question is not simply whether the share price is moving on a …

Ankur Sharma | 14 October 2026

IXICO (LSE:IXI, AIM): Can Clinical-Trial Demand Support a More Consistent Growth Path?

IXICO PLC (LSE:IXI) sits within the healthcare universe of the London Stock Exchange. As of 14 October 2026, the most useful way to assess the shares is to connect the company’s latest available corporate context with the specific evidence that could change its outlook.

Ankur Sharma | 14 October 2026

Physiomics plc (LSE:PYC): The Next Catalyst Investors Should Watch on the AIM Market

Physiomics plc (LSE:PYC) is a company to assess through the lens of mathematical modelling and simulation services for pharmaceutical and biotechnology research. For investors following the London Stock Exchange’s AIM market, the central question is not simply whether the share price is moving on …

Ankur Sharma | 14 October 2026

Avacta (LSE:AVCT): Clinical updates put its oncology pipeline back in focus

Avacta Group (LSE:AVCT) is attracting attention on 14 October 2026 after the company's latest update: presentation on ava6000 and ava6103 at esmo 2026. The announcement matters because investors are weighing not only the immediate headline but also its implications for future earnings, cash generation, …

Ankur Sharma | 14 October 2026

CelLBxHealth (LSE:CLBX): US pharmaceutical work statement raises questions over commercial conversion

CelLBxHealth (LSE:CLBX) is attracting attention on 14 October 2026 after the company's latest update: new statement of work with a us pharmaceutical company. The announcement matters because investors are weighing not only the immediate headline but also its implications for future earnings, cash generation, …

Ankur Sharma | 14 October 2026

Verici Dx (LSE:VRCI): Ownership notice keeps attention on a developing diagnostics story

Verici Dx (LSE:VRCI) is attracting attention on 14 October 2026 after the company's latest update: holding in company. The announcement matters because investors are weighing not only the immediate headline but also its implications for future earnings, cash generation, funding requirements and strategic execution. …

Ankur Sharma | 14 October 2026

Arecor Therapeutics (LSE:AREC, AIM) Draws Attention to the Commercial Value of Its Formulation Platform

Arecor Therapeutics PLC (LSE:AREC) sits within the healthcare universe of the London Stock Exchange. As of 14 October 2026, the most useful way to assess the shares is to connect the company’s latest available corporate context with the specific evidence that could change its …

Ankur Sharma | 14 October 2026

Cambridge Cognition Holdings plc (LSE:COG): The Next Catalyst Investors Should Watch on the AIM Market

Cambridge Cognition Holdings plc (LSE:COG) is a company to assess through the lens of digital cognitive assessments and technology used in clinical trials and brain-health research. For investors following the London Stock Exchange’s AIM market, the central question is not simply whether the share …

Ankur Sharma | 14 October 2026

Coiled Therapeutics plc (LSE:COIL): The Next Catalyst Investors Should Watch on the AIM Market

Coiled Therapeutics plc (LSE:COIL) is a company to assess through the lens of therapeutics and drug-development research. For investors following the London Stock Exchange’s AIM market, the central question is not simply whether the share price is moving on a particular session. It is …

Ankur Sharma | 14 October 2026
Support

Hi! How can we help you today?

Loading…